Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Climb Bio (CLYM) Total Current Liabilities (2020 - 2026)

Climb Bio filings provide 7 years of Total Current Liabilities readings, the most recent being $4.1 million for Q1 2026.

  • Quarterly Total Current Liabilities fell 42.14% to $4.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4.1 million through Mar 2026, down 42.14% year-over-year, with the annual reading at $7.0 million for FY2025, 41.63% up from the prior year.
  • Total Current Liabilities hit $4.1 million in Q1 2026 for Climb Bio, down from $7.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $7.6 million in Q2 2022 and bottomed at $2.8 million in Q4 2023.
  • Average Total Current Liabilities over 5 years is $5.0 million, with a median of $4.9 million recorded in 2024.
  • The largest annual shift saw Total Current Liabilities tumbled 53.81% in 2023 before it soared 138.51% in 2025.
  • Climb Bio's Total Current Liabilities stood at $6.1 million in 2022, then tumbled by 53.53% to $2.8 million in 2023, then skyrocketed by 74.06% to $4.9 million in 2024, then surged by 41.63% to $7.0 million in 2025, then plummeted by 41.71% to $4.1 million in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Total Current Liabilities are $4.1 million (Q1 2026), $7.0 million (Q4 2025), and $4.9 million (Q3 2025).